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The pathology of gastric and duodenal polyps: current concepts
The liberal use of upper endoscopy has led to an
increased detection of gastric and duodenal polyps,
which are identified in as many as 6 and 4.6% of
patient examinations, respectively. Gastroduodenal
polyps are a heterogeneous group of lesions that can
be neoplastic or non-neoplastic (e.g. hyperplastic or
heterotopical). Most polyps present characteristic
topographical features, as well as endoscopic appear-
ance and size. Evaluation of the surrounding mucosa
is essential in assessing the underlying pathology
(e.g. Helicobacter pylori, autoimmune gastritis or
inherited polyposis syndromes). Phylogenetically,
gastric and duodenal polyps can be classified accord-
ing to the epithelial compartment from which they
derive. Polyps that arise from the surface epithelium
can either be of foveolar or intestinal type, and they
can develop from either the native mucosa or the
metaplastic epithelium (gastric intestinal metaplasia
or duodenal foveolar metaplasia). Other polyps
develop from the deeper glandular component, such
as pyloric/oxyntic gland derived subtypes. In this
review we focus upon epithelial polyps, with an
emphasis on the most common and clinically relevant
lesions, and present recently described entities.
Keywords: adenoma, duodenal polyp, gastric epithelial dysplasia, gastric polyp, intra-epithelial neoplasia,
polyposis syndrome
Introduction
Like the other segments of the gastrointestinal (GI)
tract, gastroduodenal polyps are a heterogeneous
group of lesions that can be either epithelial or non-
epithelial and either neoplastic or non-neoplastic (e.g.
hyperplastic or heterotopic). The liberal use of upper
endoscopy has led to an increased detection of polyps,
and gastric and duodenal polyps are identified in as
many as 6 and 4.6% of patients, respectively.1,2 In
most cases, these findings are incidental. GI polyps,
especially those that are neoplastic, have clinical
implications: they may require endoscopic surveil-
lance protocols because of their malignant potential
or, if they are manifestations of inheritable syn-
dromes, they may prompt the screening of other
organs and of family members.3 In this review, we
describe the broad variety of gastric and duodenal
polyps to help guide daily diagnostic practice. We
focus on epithelial polyps, with an emphasis on the
most common and clinically relevant lesions, and
describe several recently identified entities.
Most polyps have characteristic topographical
features as well as endoscopic appearance, size and
associated pathologies (e.g. Helicobacter pylori, autoim-
mune gastritis or inherited polyposis syndromes).1,4,5
To precisely evaluate most underlying diseases, it is
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essential to assess the mucosa surrounding the
lesions.3,4,6 It should also be pointed out that if a
patient is diagnosed with any type of gastric polyp,
the probability of their being diagnosed with a subse-
quent polyp (of any type) increases.5
Phylogenetically, gastric and duodenal polyps can
be classified according to the epithelial compartment
from which they derive. Those arising from the sur-
face epithelium, from the native mucosa or from the
metaplastic epithelium (gastric intestinal metaplasia
or duodenal foveolar metaplasia) can be either of
foveolar or intestinal type. Other polyps develop from
the deep glandular component, such as pyloric/oxyn-
tic gland-derived subtypes (Figure 1).
Gastric polyps
The prevalence of different subtypes of gastric polyps
varies depending on geographic location and predispos-
ing factors, such as Helicobacter pylori infection and
autoimmune gastritis. Furthermore, the frequency of
the occurrence of specific subtypes has changed over the
last two decades. The incidence of fundic gland polyps
(FGPs) has increased substantially with the widespread
use of proton pump inhibitors (PPIs). Conversely, follow-
ing the decreasing rate of H. pylori infection, hyperplas-
tic polyps have become less frequently observed in North
America.1,4,5,7 One study showed that the proportion of
hyperplastic polyps decreased from 48.5 to 20.8%,
whereas the proportion of FGPs increased from 8.8 to
66.1.7 In a recent study of more than 700 000 North
American patients who underwent an upper endoscopy,
it was found that 7.7% of these patients were diagnosed
with FGPs, 1.8% with hyperplastic polyps, 0.1% with
gastric adenomas and 0.06% with type I neuroen-
docrine tumours (NETs).5 More broadly, in the adult
population more than 90% of all gastric polyps are com-
prised of FGPs (47–77%) and hyperplastic polyps (17–
55%).1,4,8,9 All subtypes of adenomas (i.e. intestinal,
foveolar, pyloric and oxyntic gland variants) represent
only 1–10% of these cases.1,8–10 Of these subtypes,
intestinal-type adenomas (56%) and foveolar-type ade-
nomas (41%) are the most common;11 the prevalence of
pyloric gland adenomas (PGAs) and oxyntic gland ade-
nomas (OGAs) is not well established. PGAs were
reported to comprise 2.7% of all gastric polyps, but this
series did not account for FGPs.12
Surface epithelium-derived polyps
H Y P E R P L A S T I C P O L Y P S
Hyperplastic polyps are the second most common
type of gastric polyps, and are most frequently pre-
sent in patients during the sixth and seventh decades
of life. They are the most commonly diagnosed polyps
among children, representing 42% of all paediatric
gastric polyps. A slight female predominance is not
universally recognised.5 Hyperplastic polyps are com-
monly associated with underlying gastritis, and they
develop frequently in a background of intestinal
metaplasia (37%), H. pylori gastritis (25%), chemical/
reactive gastropathy (21%) and autoimmune gastritis
(12%). Associations with gastric antral vascular ecta-
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Figure 1. Classification of
gastric polyps according to the
mucosal compartment of
origin. *Preceded by intestinal
metaplasia. §May be preceded
by pseudopyloric metaplasia
or, according to some authors,
may represent a ‘glandular
adenoma’ resulting from
mucus neck cell differentiation
of oxyntic glands.
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Hyperplastic polyps are typically solitary and antral
predominant (60%). Multiple polyps are present in
20% of cases, and the term ‘hyperplastic polyposis’
has been used for cases with > 50 polyps. Hyperplas-
tic polyps are mainly broad-based and have a
smooth, lobulated contour. Most cases are < 20 mm
but can grow up to 120 mm in size. The risk of neo-
plastic transformation is increased for lesions
> 25 mm. Large lesions usually become eroded.
Hyperplastic polyps are composed of irregular, elon-
gated and tortuous pits with outpouchings, cystic
dilations and papillary configurations (Figure 2A).
The foveolar epithelium displays a characteristic api-
cal neutral mucin cap, which can be highlighted with
negative Alcian blue/periodic acid-Schiff (AB-PAS)
reactions. The epithelium is also immunoreactive for
mucin core protein (MUC) 5AC, but lacks expression
of intestinal markers such as MUC2, CDX2 and CD10
(Table 1). The foveolar cells can develop overt
hypertrophic features, with the formation of clustered
pseudogoblet cells or even pseudosignet-ring
cells – especially in damaged areas. Pseudogoblet cells
are shown to be filled with slightly pinkish mucin on
haematoxylin and eosin (H&E)-stained slides (as
opposed to the blueish hue of true goblet cells)
(Figure 2F). Helicobacter pylori infection is present in
6–20% of hyperplastic polyps,5,14 and polyps may
regress after antibiotic therapy.15 The lamina propria
is characteristically oedematous, with variable num-
bers of lymphocytes, plasma cells and eosinophils. An
eroded surface attracts a marked granulocytic infil-
trate and is associated with mucin-depleted regenera-
tive epithelium, with nuclear hyperchromasia and
enlarged nucleoli that can mimic dysplasia. Some
hyperplastic polyps can exhibit thick-walled blood
vessels and prominent smooth muscle bundles that
radiate from the deep muscularis mucosae, owing to
a mucosal prolapse phenomenon (Figure 2B); these
cases are commonly observed in the antropyloric
region and are more frequently sessile than the clas-
sic variant.14 Intestinal metaplasia (4–16%) and
(rarely) dysplasia (4%) can be detected. Dysplastic foci
may exhibit both foveolar end intestinal pheno-
types,16 the histological features of which are detailed
in the adenoma section in the present article. It is
worth noting that, in some series, dysplasia is more
often diagnosed in the surrounding flat mucosa than
in the polyp proper.8 The reported rate of malignant
transformation shows considerable differences from




Figure 2. Gastric hyperplastic
polyps: subtypes and
differential diagnoses. A, The
classic hyperplastic polyp,
while (B) shows a lesion with
prominent blood vessels and
radiating smooth muscle
bundles probably indicative of
mucosal prolapse
phenomenon. B, A juvenile
polyp, notoriously difficult to
differentiate in superficial
biopsy material. Peutz–Jeghers
polyps (D) can be distinguished
from hyperplastic polyps by the
recognition of smooth muscle
nesting or arborising (insert).
However, this unique feature is
uncommon. Cronkhite–Canada
syndrome diffusely involves the
gastric mucosa, with more
polypoid areas reminiscent of
inflammatory or juvenile
polyps (E). F, ‘Pseudogoblet’
cells, a common cytological
change in foveolar hyperplasia,
that should not be mistaken
for true goblet cells.
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polyps harbouring dysplasia or adenocarcinoma are
more than 20 mm in size.17,19
To date, most studies have reported an absence of
pathogenic mutations in small non-dysplastic hyper-
plastic polyps, which implies a truly non-neoplastic
and reparative/hyperplastic nature. However, genetic
alterations have been identified in large hyperplastic
polyps, especially in those associated with dysplasia
or adenocarcinoma (Table 1).20,21 Detected immuno-
histochemical and molecular abnormalities include
loss of O6-methylguanine-DNA methyl-transferase
(MGMT) expression, APC or CTNNB1 (beta-catenin)
mutations, and less frequently KRAS or BRAF alter-
ations.22 Dysplastic hyperplastic polyps also fre-
quently harbour TP53 mutations, and p53
immunohistochemistry has been used as an ancillary
technique for the differential diagnosis of reactive aty-
pia versus dysplasia.23 The differential diagnosis of
hyperplastic polyps includes regenerative foveolar
exophytic growth, such as reactive polypoid foveolar
hyperplasia, which is frequently associated with reac-
tive gastropathy and detected in the antropyloric
region, adjacent to erosions or ulcers. Reactive poly-
poid foveolar hyperplasia is usually sessile and smal-
ler than hyperplastic polyps.
Another lesion to rule out is gastritis cystica glan-
dularis/profunda, which develops in patients with
previous gastrectomy or stomas and is characterised
by cystically dilated glands herniated into the submu-
cosa and muscularis propria. Furthermore, hamar-
tomatous polyps show considerable morphological
overlap with hyperplastic polyps and can be virtually
indistinguishable (Table 3). Some subtle histological
features can be suggestive of the diagnosis; however,
it is frequently impossible to identify these features in
superficial biopsies and in the absence of proper clini-
cal information.
Juvenile polyps present with large cystically dilated
glands and an overtly oedematous stroma that is rich
in neutrophil granulocytes (Figure 2C), whereas
Peutz–Jeghers polyps may contain, in rare cases, the
characteristic arbourising smooth muscle bundles (Fig-
ure 2D). However, in some examples, desmin immuno-
histochemistry can demonstrate a nesting pattern/
lobulated arrangement. Menetrier disease and
Cronkhite–Canada syndrome may also need to be ruled
out. The most important differentiating feature of these
conditions is their diffuse mucosal involvement rather
than the formation of distinct polyps. Menetrier disease
shows glandular atrophy of the oxyntic mucosa and
lacks significant inflammation. Mucosal polypoid areas
in Cronkhite–Canada syndrome can resemble inflam-
matory or juvenile polyps, with a mixed inflammatory
infiltrate that is rich in eosinophils in the lamina pro-
pria and the glandular epithelium as well as crypt
abscesses (Figure 2E).24 In Cowden disease, the pecu-
liar diverse stromal attributes may assist in reaching
an accurate diagnosis.24 Finally, low-grade foveolar
adenomas can be particularly difficult to diagnose
because the dysplastic changes can be subtle and mis-
diagnosed as hyperplastic polyps.
The management of hyperplastic polyps is deter-
mined by the size of the lesions and whether dys-
plasia is detected (Table 2). Endoscopic resection is
advised for polyps that harbour biopsy-proven dys-





















Pyloric gland adenoma Gastric heterotopia/
Brunner gland
proliferative lesions
PAS: no mucin cap
MUC6+++
MUC5AC+
GNAS and KRAS Reactive atypia in proliferative
Brunner gland lesions
Other adenomas (especially
intestinal and pyloric gland
adenoma)
Adenocarcinoma
AB, alcian blue; FAP, familial adenomatous polyposis; FGP, fundic gland polyp; MUC, mucin core protein; PAS, periodic acid–Schiff.
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morphology and are symptomatic. Antibiotic therapy
and re-endoscopy have been suggested for patients
with H. pylori gastritis, although large polyps
(> 30 mm) should be resected. The background
mucosa should also be evaluated for atrophic gastri-
tis and intestinal metaplasia. Subsequent endoscopic
surveillance for gastric neoplasia is recommended,
depending on the stage of preneoplastic changes.3
S U R F A C E E P I T H E L I U M - D E R I V E D A D E N O M A S
( F O V E O L A R A N D I N T E S T I N A L A D E N O M A S )
In contrast to gastric epithelial dysplasias, which are
endoscopically flat, gastric adenomas are exophytic/
polypoid dysplastic epithelial growths that bulge into
the lumen. Gastric adenomas are rarely detected in
otherwise normal mucosa but usually develop on
the background of mucosal injury. Adenomas repre-
sent direct precursors of adenocarcinomas and indi-
cate a higher risk of adenocarcinoma elsewhere in
the stomach. Two histological types of adenomas are
recognised. Intestinal-type adenoma represents 56%
of cases and can be regarded as the conventional
form, morphologically similar to conventional colo-
nic adenomas. Foveolar-type adenoma (or type II
dysplasia) represents 41% of the cases. Gastric foveo-
lar dysplasia, which develops in FGPs of patients
with familial adenomatous polyposis (FAP), is a bio-
logically distinct entity with regard to prevalence,
progression and treatment. It is discussed in the FGP
section of the present article.
Gastric adenomas are usually diagnosed inciden-
tally. Their incidence increases with age
(peak = 70s–80s), with a male predominance (2:1
male to female ratio). In a US cohort study, Abra-
ham et al. reported chronic gastritis, intestinal meta-
plasia, gastric atrophy, autoimmune gastritis and
H. pylori infection to be associated with the intestinal
phenotype, and the foveolar phenotype to arise in
normal gastric mucosa.11 Conversely, the Korean
series of Park et al. showed no difference between
either histological type in the mucosal background.25
Gastric enterochromaffin-like cell NETs, another
complication of autoimmune gastritis, are frequently
(odds ratio = 19) diagnosed in patients with adeno-
mas.5
Most gastric adenomas are localised in the antrum
and present as solitary lesions (82%).11 Although
they can be multiple, true adenomatous polyposis of
the stomach has never been reported. Adenomas
range in size from a few millimetres to several cen-
timetres and may be sessile or pedunculated.

















































































































































































































































































































































































































































































































































































































































































































































© 2020 The Authors. Histopathology published by John Wiley & Sons Ltd, Histopathology, 78, 106–124.
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































© 2020 The Authors. Histopathology published by John Wiley & Sons Ltd, Histopathology, 78, 106–124.
112 B Kovari et al.
(> 20 mm), smaller adenomas can also harbour inva-
sive adenocarcinoma.19 The recently described rasp-
berry-like endoscopic variant of adenoma that
develops in a non-atrophic, H. pylori-negative mucosa
has been proposed as a distinct presentation of foveo-
lar adenoma. Due to their morphological similarities
with hyperplastic polyps and their usually low degree
of atypia, hyperplastic polyp-like lesions arising in
otherwise healthy mucosa should be thoroughly eval-
uated to exclude a low-grade foveolar adenoma.26
Gastric intestinal and foveolar adenoma can usu-
ally be diagnosed and subtyped using H&E slides
(Table 1). Intestinal adenomas are fundamentally
indistinguishable from colonic adenomas. They are
characterised by pseudostratified columnar epithe-
lium, elongated, pencil-shaped and overlapping nuclei
and clumped chromatin. A variable number of inter-
spersed goblet cells (Figure 3) can be observed.
Paneth cells, absorptive cells with a brush border and
even neuroendocrine cells are commonly detected.25
Most polyps have a tubular growth pattern, but
tubulovillous or villous architecture can also be
observed. Like hyperplastic polyps, foveolar adenomas
are composed of columnar or cuboidal foveolar
epithelium with an apical neutral mucin cap (Fig-
ure 4). Although the diagnosis of adenoma requires
unequivocal neoplastic features, low-grade polyps can
be challenging to distinguish from hyperplastic/regen-
erative foveolar epithelium (with their small round-
to-oval cells and basally orientated nuclei) without
considerable stratification. Foveolar adenomas char-
acteristically express MUC5AC and variably MUC6,
whereas intestinal-type adenomas are positive for
MUC2, CD10 and CDX2. In addition, many polyps
with indeterminate or hybrid features are recognis-
able. On H&E stains, some cases devoid of characteris-
tic cytoplasmic mucin production (reminiscent of
either goblet cells or foveolar cells) may be classified
as indeterminate (3.3%).11 Hybrid lesions with
expression of both intestinal and gastric markers are
detectable via immunohistochemistry.25 However,
routine subtyping is not recommended due to a lack
of proven clinical relevance.
Both histological subtypes of gastric adenoma har-
bour alterations in the APC, KRAS, ERBB3 and TP53
genes and may also show mismatch repair (MMR)
gene inactivation (Table 1).27 No significant differ-
ence in the frequency of specific molecular alterations
has been detected between the two phenotypical vari-
ants.28 Interestingly, several studies have demon-
strated that APC-mutated gastric dysplasia may be
considered a more indolent tumour, which rarely pro-
gresses to adenocarcinoma, whereas dysplasia with a
TP53 mutation could represent a more aggressive
subtype.29,30 Whether p53 immunohistochemistry
can be used as a predictive biomarker of progression
has not been investigated, and whether intestinal and
foveolar-type adenomas behave differently is con-
tested (Table 2). Whereas Abraham et al. suggested
that the intestinal phenotype is more frequently asso-
ciated with high-grade dysplasia and malignant
transformation,11 Park et al. reported that foveolar
lesions are frequently detected with high-grade mor-
phology.25 Nevertheless, these two studies used differ-
ent definitions (H&E versus immunohistochemistry)
and were based on two different populations (North
American and South Korean). A Portuguese study
evaluating non-polypoid gastric dysplasias also con-
cluded that the foveolar phenotype is the biologically
more aggressive subtype of the two.31
Gastric adenomas should be resected endoscopically
when technically possible. Endoscopic mucosal resec-
tion (EMR) is usually preferred for the removal of
smaller lesions. In contrast, endoscopic submucosal
dissection is advisable for larger (> 15 mm) or broad-
based polyps to achieve negative margins and
because of the higher risk of invasive neoplasia. Endo-
scopic surveillance should be performed 6–12 months
after excision and annually thereafter. An assessment
of the background mucosa should be performed to
identify synchronous neoplasia, gastric atrophy or
intestinal metaplasia.3
A B
Figure 3. Gastric intestinal




© 2020 The Authors. Histopathology published by John Wiley & Sons Ltd, Histopathology, 78, 106–124.
Pathology of gastric and duodenal polyps 113
Gastric (oxyntic) gland-derived polyps/
adenomas
The category of gastric (oxyntic) gland-derived
polyps/adenomas incorporates FGPs as well as rarer
lesions, such as PGAs and OGAs. Given their shared
GNAS mutations,32–34 PGAs and OGAs are thought
to represent diverse manifestations along a single
spectrum of lesions, with the ability to differentiate
between the various cell types of the oxyntic gland.
Accordingly, gastric glandular adenomas with pre-
dominantly parietal and chief cell differentiation are
equivalent to OGAs, whereas tumours predominantly
composed of mucous neck cells are analogous to
PGAs.32 This observation is also supported by the
occurrence of hybrid lesions with mixed cell types
and the unique location of these polyps.
Fundic gland polyps
FGPs develop in various clinical settings: as a conse-
quence of PPI therapy; sporadically; in hereditary
polyposis syndromes (Table 3), such as FAP,35 gastric
adenocarcinoma proximal polyposis of the stomach
(GAPPS)36 and rarely MUTYH-associated polyposis
(MAP);37 and possibly in patients with Zollinger–Elli-
son syndrome. Because of the growing use of PPI, the
incidence of FGP has increased substantially in the
last two decades, although geographical heterogene-
ity exists due to the variable prevalence of PPI ther-
apy and H. pylori infection (which can inhibit the
formation of FGP). Non-syndromic polyps are most
frequently diagnosed at 40–60 years of age, with a
female predominance. In the syndromic setting, FGPs
usually develop at a younger age (20–40 years),
without a gender predilection. Rarely are FGPs seen
in paediatric patients, a diagnosis that should prompt
evaluation for syndromic association. FGPs are less
commonly detected in the setting of gastritis, H. pylori
infection, intestinal metaplasia or atrophy than in
normal controls. The knowledge of ongoing PPI ther-
apy, or positive family history for FAP, GAPPS or
MAP may support the diagnosis.5
FGPs present as small (1–7 mm), round, translu-
cent polyps that have a smooth surface. They arise
exclusively in the oxyntic mucosa, surrounded by an
endoscopically otherwise-normal mucosa. Sporadic
cases typically appear as a solitary polyp; however,
up to 25% of non-syndromic patients may develop
multiple (usually 2–15) FGPs. In the syndromic set-
ting, 40–80% of patients with FAP and most patients
with GAPPS are detected with more than 100 polyps.
Microscopically, FGPs show cystically dilated fundic
glands that are lined predominantly with parietal
cells and, variably, chief cells or foveolar/mucous
neck cells (Table 1). The FGPs of patients on PPI
therapy tend to develop markedly dilated fundic gland
cysts, foveolar cell hyperplasia and parietal cells with
cytoplasmic blebs projecting into the lumen, which
creates a hobnail morphology (Figure 5A).38 Parietal




Figure 4. Gastric foveolar adenoma. This broad-base (A), villiform (B)
dysplastic lesion is lined by tall clear foveolar cells with distinct mucin
cap (C).
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background mucosa of patients on PPI therapy.
Inheritable polyposis-related polyps present different
attributes (Figure 5B,C).39 FAP-related FGPs are usu-
ally smaller and more frequently display small micro-
cysts that are almost solely lined by fundic epithelium
without significant parietal cell hyperplasia. The sur-
face is usually devoid of foveolar hyperplasia. GAPPS-
associated FGPs are large, with prominent microcysts
lined with predominantly foveolar-type epithelium
and inverted foveolar hyperplasia or hyperprolifera-
tive aberrant pits. Parietal cell hyperplasia is an
uncommon feature. Dysplastic transformation is rare
in non-syndromic cases (1%).40 Alternatively, in syn-
dromic FGPs, there is a 25–46% frequency of dysplas-
tic transformation, usually of foveolar type.41 The
progression rate from low- to high-grade dysplasia or
adenocarcinoma is low (4% in 6-year mean follow-
up) in FAP-related cases41 but higher among patient
with GAPPS (Table 2).36
FGPs have been classically regarded as hamartoma-
tous lesions. Recently, based on the detection of vary-
ing genetic alterations (Table 1), it was reported that
most FGPs are clonal lesions. Sporadic FGPs harbour
activating CTNNB1 (b-catenin) mutations in 10–90%
of cases,38,42 and FAP-related dysplastic FGPs show
somatic APC gene alterations in 50% of cases.35
GAPPS families have been identified to have point
mutations in the promoter 1B of APC gene,36 whereas
patients with MAP are affected by bi-allelic mutations
in the MUTYH gene encoding DNA repair (base exci-
sion pathway) protein.37 Whether sporadic FGPs
should be considered neoplastic rather than hamar-
tomatous lesions is still debated as a matter of how
neoplasia should be defined. Regardless of this noso-
logical conundrum, dysplastic changes are extremely
rare in sporadic FGPs, and progression to adenocarci-
noma has never been reported. In our opinion, the
presence of genetic alterations supports a true clonal
origin, and the lack of cytological atypia and very
low potential to progress into malignancy do not con-
tradict the possibility of a neoplastic nature, given
that this absence is accepted for other well-differenti-
ated neoplasms (e.g. uterine leiomyomas).
In the absence of atypical features, such as large
size (> 10 mm), antral location or ulceration,
removal is not required. Targeted biopsies can be con-
sidered when excision is not possible. PPI-associated
cases should be reviewed for the indication of the PPI
therapy and appropriateness of the dosage; further-
more, alternative treatments should be considered.
Surveillance endoscopy is not needed in non-syn-
dromic cases. As mentioned earlier, the possibility of
syndromic FGPs should be considered when treating
young patients (aged < 40 years) and in cases with a
large number of polyps (> 20) and a suspicion of dys-
plastic changes (atypical surface or vascular pattern).
The presence of simultaneous duodenal adenomas




Figure 5. Fundic gland polyp (FGP). Histological variability of FGPs
in relation to the clinical association. Note the difference between
(A), the typical proton pump inhibitor (PPI)-associated FGP, in
comparison to (B) a smaller familial adenomatous polyposis (FAP)-
associated FGP and (C) larger gastric adenocarcinoma proximal
polyposis of the stomach (GAPPS)-associated polyp.
© 2020 The Authors. Histopathology published by John Wiley & Sons Ltd, Histopathology, 78, 106–124.
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FGPs should be endoscopically resected and patients
subjected to annual follow-up.3
Pyloric gland adenoma
PGAs most frequently present in the stomach,12,43,44
although they can also develop in the oesophagus,45
duodenum,12,46 rectum,47 gallbladder12,48 and bile
ducts.12 Gastric PGAs mainly develop in three clinico-
pathological settings: the chronic atrophic gastritis-as-
sociated setting (particularly autoimmune gastritis),
the hereditary cancer predisposition syndrome-associ-
ated setting (Table 3) and, sporadically, in the normal
mucosal background. Presumably, due to the high
proportion of autoimmune gastritis, PGAs primarily
occur in females (52%), and the mean age at diagno-
sis is in the seventh decade. Syndromic cases occur at
a younger age.49,50 The association with adenocarci-
noma initially noted in 12–30% of cases has not been
confirmed by recent series.12,51 PGA is only one
among various types of polyps more commonly
detected in the setting of autoimmune gastritis, along
with hyperplastic polyps and NETs.12,49,51 PGAs have
also been detected in patients with FAP, Lynch syn-
drome and juvenile polyposis syndrome
(JPS).32,44,49,50,52–54 Nevertheless, in more than a
third of these cases, no underlying gastric disease has
been identified.12,49
Gastric PGAs are most often detected in the oxyn-
tic mucosa, with a mean size of 20 mm. Low-grade
PGAs are composed of tightly packed, uniform
tubules lined by a monolayer of cuboidal to low
columnar cells with pale eosinophilic cytoplasm as
well as basal, round nuclei and open chromatin
(Figure 6, Table 1).12,43,44,49,51,55 The cells show a
characteristic ground-glass appearance and, unlike
foveolar cells, do not have a well-formed apical
mucin cap. The stroma is usually scant. High-grade
lesions display a more complex architecture, often of
cribriform appearance, and worrisome cytological
features, including a higher nucleus to cytoplasm
ratio, hyperchromasia, loss of nuclear polarity and
prominent nucleoli.51 Due to decreased mucin pro-
duction the cytoplasm can be more eosinophilic.
Immunohistochemically, the hallmark of pyloric
gland differentiation is MUC6 expression, although
positivity for the primarily foveolar marker MUC5AC
is frequently detected at least focally.43,44,51,55
Recently, three patterns have been recognised:
‘mixed type’ (the most common, with variable pro-
portions of MUC6 and MUC5AC labelling), ‘pure
pyloric type’ (characterised by diffuse MUC6 staining
but with MUC5AC still expressed in the superficially
overlying foveolar epithelium) and a rare ‘predomi-




Figure 6. Pyloric gland adenoma. A and B, Typical low- and med-
ium-power view of a low-grade tubulovillous pyloric gland ade-
noma (PGA). C, High-power view of another example of PGA with
high-grade nuclear features.
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and MUC6 positivity limited to the basal portion of
the glands).49
The most prevalent molecular alterations detected
are the activating mutation of GNAS (63–83%) and
KRAS (41–67%);33,52 p53 overexpression and
nuclear b-catenin expression can also be
observed.33,56 FAP-associated and sporadic PGAs
have generally similar genetic alterations, although
the frequency of APC mutations is higher in FAP-as-
sociated cases (100 versus 44%).52 Deficient MMR
protein expression can be detected in PGAs of patients
with Lynch syndrome but not in sporadic cases
(Table 1).50 No specific guidelines have been proposed
regarding the management of PGAs. However, we
suggest following the general guidelines established
for the treatment of typical gastric adenomas.
Oxyntic gland adenoma
Oxyntic gland adenoma has only recently been recog-
nised. Characteristically, OGA differentiates towards
chief cells, parietal cells and mucus neck cells, thereby
recapitulating the normal cellular components of oxyn-
tic glands. Given the clinical conundrum of their beha-
viour, alternative terms for oxyntic gland neoplasm
have been proposed to denote the whole spectrum of
tumours with oxyntic gland differentiation, including
gastric adenocarcinomas of fundic gland type.34 The
mean age of patients with OGA is 66 years, with a male
predominance (male to female ratio = 3:1). Endoscopi-
cally, most OGA lesions are identified in the gastric body
and fundus. They are usually elevated, with a reported
size ranging from 3 to 40 mm.34
Microscopically, OGAs can display a chief cell-pre-
dominant pattern, an admixture of chief and parietal
cells resembling normal fundic glands, and a predom-
inant mucous neck cell and foveolar differentiation
pattern.34,57,58 The latter subtype is usually observed
in larger lesions, which could represent a more
aggressive variant.34 Architecturally, OGAs are com-
posed of tightly packed tubules and trabeculae.
Nuclear atypia is usually mild to moderate (Fig-
ure 7A,B). Mitotic figures are rare. In contrast, high-
grade OGAs are characterised by complex anastomos-
ing glands and more pronounced cytonuclear atypia
(Table 1). Careful assessment of the submucosa is
essential, because herniation through the muscularis
mucosae is relatively common and should not be con-
strued as evidence of invasion. Based on the favour-
able outcome of oxyntic gland neoplasms with such
submucosal involvement, Singhi et al. suggested that
this finding might represent prolapse-type epithelial
misplacement, and they proposed to reclassify gastric
adenocarcinomas of fundic gland type as OGAs.59
Nevertheless, studies with Japanese cohorts have
shown cases of oxyntic gland neoplasms with massive
submucosal extension, lymphovascular invasion and
lymph node metastasis as well as possible predictive
factors of malignant behaviour, such as the degree of
nuclear atypia and mucus neck cell differentiation
(Table 2).34 Although the diagnosis of OGA should
primarily rely upon the result of H&E stains, the chief
A B
C D
Figure 7. Oxyntic gland
adenoma. This composite
illustrates the morphological
features (A,B), whereas (C) and
(D), respectively, show
pepsinogen-I immunoreactivity
of chief cells (C) and H+/K+-
ATPase immunostaining of
parietal cells.
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cell and parietal cell components can be highlighted
with pepsinogen-I and H+/K+-ATPase immunostain-
ing, respectively (Figure 7C,D). Similar to PGAs,
MUC6 can be diffusely expressed (Table 1),60 and the
Ki-67 labelling index is usually low. To date, studies
are limited; however, in 50% of lesions observed in
these reports, mutations of various genes involved in
the Wnt/b-catenin signalling pathway, such as
CTNNB1, AXINs, APC or GNAS, have been
detected.61,62 No specific guidelines have been estab-
lished for the management of OGA. However, size,
degree of atypia and invasion should be the guiding
principles for advising endoscopic therapy.
Duodenal polyps
Duodenal polyps are commonly defined on the basis
of their location – either in the duodenal bulb,
ampullary/peri-ampullary region or distal duodenum.
Some lesions are almost exclusively diagnosed in the
ampullary/peri-ampullary region (e.g. tumours of
pancreatobiliary differentiation, gangliocytic paragan-
gliomas and somatostatin-expressing neuroendocrine
tumours) and form a distinct group. However, these
lesions are not discussed in this review.
Most duodenal polyps are non-neoplastic. Instead,
they represent regenerative/hyperplastic nodules of
foveolar epithelium or Brunner gland proliferations
(38%). Other less common polyps include heterotopic
(6%) and neoplastic lesions (11%).63 Adenomas of
intestinal-type are the most common (89%), followed
by adenomatous lesions that present a gastric pheno-
type: PGAs (8%) and foveolar-type adenomas (3%).64
Non-neoplastic polyps
Non-neoplastic duodenal polyps, most of which repre-
sent regenerative inflammatory (pseudo) polyps, are
predominantly localised in the bulb (80%).63 The
majority are associated with duodenitis, especially in
the setting of peptic injury, and are less commonly
associated with inflammatory bowel disease or rare
conditions such as primary immunodeficiencies.65
Histologically, non-neoplastic duodenal polyps may
resemble gastric hyperplastic polyps and frequently
show metaplastic foveolar epithelium with active
inflammation and/or erosion, reactive epithelial
changes, seamless transition with the surrounding
epithelium and surface maturation (Figure 8A,B).
They may also simply be composed of granulation tis-
sue. It is worth underscoring that some of these
polyps are neoplastic. Some hyperplastic polyps
harbour KRAS and BRAF mutations and tend to
show serrated features, similar to their microvesicular




Figure 8. Non-neoplastic duodenal polyps. Polypoid exuberant
regenerative foveolar hyperplasia (A). The absence of unequivocally
neoplastic atypia, the active inflammation and/or erosion, reactive
epithelial changes with a seamless transition to the surrounding
epithelium and surface maturation differentiate this lesion from a
foveolar adenoma (B). Brunner’s gland proliferative lesions (C*)
should be differentiated from pyloric gland adenomas (PGAs). A dis-
tinctive feature is the retained lobular architecture, highlighted by
the presence of fibrous and smooth muscle septae (*courtesy of Dr
A. Srivastava, Brigham and Women’s Hospital, Boston, MA, USA).
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out that duodenal hyperplastic polyps with KRAS
mutation may represent precursor lesions of duodenal
traditional serrated adenomas.66 Polypoid heterotopic
gastric mucosa is another frequent type of duodenal
polyps. As opposed to the peptic injury-induced foveo-
lar metaplasia, lesions of this type also contain clus-
ters of oxyntic glands under the surface of the
foveolar epithelium. Duodenal gastric heterotopia has
been shown to be associated with FGPs and PPI ther-
apy, but to have an inverse association with H. pylori
infection. It has been postulated that microscopic
heterotopic oxyntic mucosal islands become polypoid
in response to PPI therapy-induced hyperplasia/hy-
pertrophy.67 A further similarity with gastric FGPs is
the detection of somatic CTNNB1 (b-catenin) gene
mutations, which implies the possibility of a neoplas-
tic condition. Conversely, such molecular alterations
are absent in peptic injury-related foveolar metapla-
sia.68 Deeply located Brunner glands may also show
various degrees of regenerative proliferation and reac-
tive atypia and form Brunner gland hyperplasia/
hamartoma.69 This diagnostic category is not well
defined, and the use of ‘Brunner gland proliferative
lesions’ as a generic term has been encouraged.70
Notably, gastric heterotopia and Brunner gland prolif-
erative lesions have both been advanced as possible
precursor lesions of duodenal PGAs.51 The presence
of fibrous and smooth muscle septae and intermingled
adipose tissue, which highlights the retained lobular
architecture, can help to distinguish Brunner gland
proliferative lesions from PGAs (Figure 8C).71
Surface epithelium-derived adenomas
(foveolar and intestinal adenomas)
The duodenum (particularly the second portion) is
predisposed to the development of small intestinal
adenomas.63 The mean age of patients at diagnosis is
65 years, with a slight male predilection. In contrast
to gastric adenomas, which are predominantly non-
syndromic in nature, a relatively high proportion (ap-
proximately 60%) of non-ampullary duodenal
adenomas are associated with FAP or MAP (Table 3).
Non-syndromic non-ampullary adenomas are found
in only 0.3–0.5% of gastroduodenoscopies. Most duo-
denal adenomas present endoscopically as sessile
rather than pedunculated lesions.72
Histologically, most adenomas are of intestinal
type, but foveolar-type adenomas can also develop
(Table 1). Intestinal adenomas are essentially identi-
cal to colonic adenomas, with predominantly tubular
but sometimes tubulovillous or villous architecture.
They are formed of pseudostratified absorptive cells
that are intermingled with goblet and Paneth cells
(Figure 9). There are no histological features by
which FAP- and MAP-related cases can be distin-
guished. Foveolar adenomas show tall columnar
epithelium that resembles gastric foveolar cells and
has a characteristic apical mucin cap (Figure 10).
These adenomas usually display a tubulovillous archi-
tecture.64,73 Based on limited data, it has been found
that foveolar adenomas could have a higher tendency
to harbour high-grade dysplasia.64 These lesions uni-
formly express MUC5AC, with scattered MUC6-posi-
tive cells, whereas intestinal adenomas can be
labelled with CDX2, CD10 and MUC2.64,73,74 APC
and KRAS alterations are frequently identified in both
non-syndromic and FAP-related intestinal adenomas
(Table 1). DNA MMR abnormalities, TP53 and BRAF
mutations are infrequent.75 The risk of neoplastic pro-
gression appears to be related to the size and grade of
dysplasia with low-grade lesions and those < 20 mm
in size presenting a low risk of progression to adeno-
carcinoma (4.7%). Conversely, biopsy-proven high-
grade lesions are frequently (approximately 55%)
found to contain adenocarcinoma after endoscopic
resection (Table 2).76 Cold-snare polypectomy is rec-
ommended for the excision of small sporadic non-am-
pullary duodenal adenomas (< 10 mm). Due to the
higher association with high-grade dysplasia or adeno-
carcinoma, larger (> 10 mm) lesions can be effectively
removed by EMR. Endoscopic submucosal dissection is
not recommended because of the relatively thin and
vascular nature of the duodenal wall, which has a rel-
atively high risk of perforation (up to 30%).77
A B
Figure 9. Duodenal intestinal
adenoma. This adenoma is
similar to conventional colonic
adenomas (A), with CD10
immunostaining highlighting
the brush border (B).
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Duodenal adenomas with pyloric gland
phenotype
The pathogenesis of duodenal PGAs is unknown. The
hypothesis that they arise either from heterotopic gas-
tric mucosa or regenerative Brunner glands is the
most convincing to date.51 The diagnostic category of
Brunner gland adenoma remains controversial and is
not well described. In fact, most published cases of




Figure 10. Duodenal foveolar adenoma. This villiform dysplastic
lesion (A) is characteristically decorated by diffuse mucin core pro-
tein (MUC)5AC immunoreactivity (B) and lined by tall clear foveo-




Figure 11. Duodenal pyloric gland adenoma. The polyp is com-
posed of packed clear to eosinophilic tubular glands (A) and high-
lighted by mucin core protein (MUC)6 immunoreactivity (B). C,
Characteristic high-magnification morphology.
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of PGAs. In the opinion of many authors, to be con-
sistent with the gastric nomenclature it is preferable
to use the term ‘PGA’ rather than ‘Brunner gland
adenoma’.70
Duodenal PGAs are morphologically similar to gas-
tric PGAs. Most are endoscopically polypoid, but flat
lesions have been reported.12,51 They are commonly
located in the proximal duodenum. Microscopically,
they are composed of tightly packed tubules that are
lined by a monolayer of cuboidal cells and have gran-
ular-eosinophilic to ground-glass cytoplasm and lack
an apical mucin cap (Figure 11, Table 1).12,51 High-
grade lesions contain complex or cribriform glands,
with an increased nucleus:cytoplasm ratio, prominent
nucleoli, pleomorphism and loss of cell polarity.51
PGAs show diffuse and strong MUC6 and MUC5AC
labelling, in contrast to the negative MUC6 staining
in foveolar lesions.64,74,78
Reactive Brunner gland proliferative lesions (e.g.
Brunner gland hamartoma/hyperplasia) can be differ-
entiated from PGAs primarily by their retained lobular
architecture. Although low-grade PGAs also show rela-
tively uniform cytology, Brunner gland proliferative
lesions lack the at least minimally enlarged nuclei of
PGAs with their open chromatin and small nucleoli.71
Like their gastric counterparts, duodenal PGAs fre-
quently harbour mutations in GNAS and KRAS,33,78
which were also recently detected in duodenal gastric
heterotopia (Table 1).79 Interestingly, in contrast to
gastric PGAs, the duodenal equivalents are uncom-
monly detected in a syndromic setting (e.g. in FAP,
JPS or Lynch syndrome).32,50,52–54,78 Because of the
rarity of these lesions and the lack of large-scale ser-
ies with regard to their natural history and prognosis,
no therapeutic recommendations have been pub-
lished. Alarming rates of progression to invasive car-
cinoma (10.5–66%) have been reported in a few
small series,12,51,64 and the likelihood of identifying
either high-grade dysplasia or invasion increases with
size (Table 2).73 Recently, a low rate of recurrence
has been reported after endoscopic removal.80
Upper GI polyps associated with tumour
predisposition syndromes
Upper GI polyps can develop in association with several
tumour predisposition syndromes and display morpho-
logical features similar to those of their non-syndromic
counterparts (Table 3).81 However, some GI polyps may
present specific dysplastic and phenotypical characteris-
tics. Furthermore, syndromic patients have different risks
of progression, which determine specific surveillance
protocols (Table 3).82,83 Tumour predisposition
syndromes usually involve both the stomach and the
duodenum and may also have colonic and/or oesopha-
geal manifestations. In some cases, the gastroduodenal
manifestations are less dramatic and clinically less
aggressive than extragastroduodenal ones (e.g. colonic
manifestations of FAP); therefore, the recognition and
diagnosis of these conditions can be challenging using
upper GI biopsies alone. Nevertheless, attempting to
establish the correct diagnosis is important because hid-
den synchronous or metachronous lesions can be identi-
fied, allowing for the adequate treatment of these
patients. Finally, it is important to bear in mind that
some familial gastric cancer syndromes (e.g. hereditary
diffuse gastric cancer and Lynch syndrome) are not asso-
ciated with polyps. These syndromes are beyond the
scope of the present review.
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